Trajectory Next will provide formalized support and guidance to companies to help them execute a pilot, establish traction, and improve their ability to attract and attain customers.
TAI Diagnostics said earlier this week that it had closed a $10 million round of funding and forged a new partnership with United Therapeutics (NASDAQ: UTHR).
GlaxoSmithKline CEO Emma Walmsley made history in 2017, when she became the first woman to head up a major pharmaceutical company.
Once heralded as a centerpiece of DC’s tech scene, start-up incubator 1776 proved less revolutionary than its name.
AstraZeneca and MedImmune, its biologics research and development arm, announced that the European Commission (EC) has approved the companies’ respiratory biologic, benralizumab, as an add-on maintenance treatment for adults with severe eosinophilic asthma that is inadequately controlled despite high-dose inhaled corticosteroids, plus long-acting b-agonists.
In recent years, Lake Whillans has published extensively on the multifaceted interplay between the legal market and the life sciences industry, specifically identifying the most active and relevant law firms for life science companies.
The Jackson Laboratory has been awarded a $3.2 million grant from the National Institutes of Health to develop an epigenome modification technology for studying gene regulation in biological processes and disease states.
PepVax, Inc., an early-stage biotechnology company, announced today that it has successfully completed the efficacy study for its lead candidate, PVX-009. The Company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to find a treatment for triple negative breast cancer (TNBC).
Icon has hired a retired colonel who is moving into the biotech sphere as new president of its subsidiary ClinicalRM. James Cummings, M.D., will lead the CRO’s unit, which helps provide research to a range of U.S. federal health agencies.
Precision for Medicine, part of Precision Medicine Group, today announced it is expanding its biomarker data management and translational informatics services into Europe. The addition of a Geneva, Switzerland-based team of experts complements Precision’s US offerings to provide clients with truly global translational research services. The Geneva team also gives Precision another European operational base, continuing Precision’s active international expansion.